#USA #Arlington #ALS Association #Ulefnersen #FUS-ALS

Landmark Progress in FUS-ALS Treatment: Ulefnersen

On September 22, 2026, the ALS Association announced thrilling news regarding ulefnersen, an investigational antisense therapy specifically designed for individuals affected by FUS-ALS. This therapy has successfully met its primary endpoint during the Phase 3 FUSION trial, showcasing promising results that could transform treatment options for this rare disease.

Ulefnersen becomes the second antisense therapy, following Qalsody (tofersen) targeted at SOD1-ALS, to offer a glimmer of hope in altering the progression of a genetic form of ALS. The clinical data indicates a considerable improvement in a combined measure of functional capabilities and survival rates for patients receiving ulefnersen compared to those given a placebo. The trial findings are accompanied by favorable data on secondary measures and an acceptable safety profile, marking a crucial milestone in ALS research and treatment.

FUS-ALS, although uncommon, holds the title of the leading cause of juvenile ALS, often leading to swift disease progression, particularly in younger individuals. These families have long faced the heartbreaking reality of not having treatment options tailored for their specific condition. The announcement by the ALS Association signals hope not only for the communities affected by this cruel form of ALS but also for those advocating for better treatment avenues.

Calaneet Balas, the president and CEO of the ALS Association, highlighted the impactful role played by Jaci Hermstad, a courageous young woman diagnosed with FUS-ALS, in promoting the research. Her advocacy efforts have been pivotal in putting pressure on the development of ulefnersen, underscoring the importance of personalized treatment solutions in the battle against ALS. Jaci, who became an inspiring figure within the ALS community, passed away in 2020, but her legacy continues to motivate the ongoing fight against the disease.

The ALS Association has been a steadfast supporter of antisense therapy research in ALS for over two decades. Their early investment in this technology, backed by dedicated donors, demonstrates the Association's commitment to finding innovative solutions to tackle ALS head-on. As more families and individuals advocate for treatments, the scientific community is energized to push forward with research and drug development.

While ulefnersen has not yet received official approval, the ALS Association urges Otsuka, Ionis, and the FDA to act swiftly to provide priority reviews and ensure that those living with FUS-ALS have access to this promising therapy. The organization remains dedicated to advocating for timely access to treatments, and they will continue to provide updates to the ALS community as developments unfold.

Conclusion

This monumental advancement in the development of ulefnersen represents a significant step forward in the ongoing fight against amyotrophic lateral sclerosis. For families affected by FUS-ALS, the hope is not just for broader access to treatment, but also for improved quality of life. The progress made in clinical trials affirms the importance of continued research and funding in the pursuit of innovative ALS therapies. As we remember Jaci Hermstad, her story inspires hope and perseverance within the ALS community, reminding us all that the fight for a cure continues.

For further information about the ALS Association and ongoing initiatives, visit als.org.